Filter posts

Blue Ribbon Study Panel Examines Surveillance and Detection Issues in Biodefense

The Blue Ribbon Study Panel on Biodefense held the third of four meetings on Thursday, …

Getting Ahead of Ebola and Other Infectious Threats—Overturning Assumptions

Ebola was one of the biggest stories of 2014 (with Ebola fighters named the TIME …

The Hill: Will Support for Biomedical Research Be Dead on Arrival?

In an op-ed over at The Hill, Dr. Claire Pomeroy, an infectious disease specialist and …

Bavarian Nordic CEO Paul Chaplin in San Jose Mercury News: Why an Ebola Vaccine Still Matters

The San Jose Mercury News this weekend published an op-ed by Paul Chaplin, the CEO …

U-T San Diego Commentary: Lack of Preparedness to Ebola Is Symptom of Larger Disease

Last week, the U-T San Diego published an op-ed by Betrand Liang, CEO of Pfenex …

BIO Presents at 2014 Biological Weapons Convention Meeting of Experts

Last week marked the annual Biological Weapons Convention (BWC) Meeting of Experts in Geneva. The …

Delivering on Biotech’s Promise to Treat Anthrax, Smallpox, Ebola

Thanks to federal biodefense programs that partner with industry to develop and stockpile medical countermeasures, …

BIO Calls for Adequate Funding of Vaccine and Biodefense Programs

It’s budget time here in Washington, with appropriators in the House and Senate working overtime …

Act Now to Protect Public Health and Prepare for the Upcoming Flu Season

As many as 49,000 people die from the flu annually, depending on the season, and …

Renewing the Project BioShield Act: What Has It Bought and Wrought?

In the next several months, the U.S. Government will decide whether to continue the funding …